Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Rakovina Therapeutics Inc
V.RKV
Alternate Symbol(s):
RKVTF
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research...
programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSXV:RKV - Post Discussion
Rakovina Therapeutics Inc
> 2021 Financial Results/Provides Corporate Update TSXV:RKV
New Post
View:
Discussion
List
(1820)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Apr 27, 2022 6:55pm
2021 Financial Results/Provides Corporate Update TSXV:RKV
VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2021 and provided a corporate update.
Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update
(28)
•••
anjz661
X
View Profile
View Bullboard History
Comment by
anjz661
on Jun 15, 2022 8:44pm
https://www.rakovinatherapeutics.com/
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition